News & Blog

News & Blog

  • Reset
Blog | Mar 15 2023

Meet the Community – Dee Smith

Community
Blog | Mar 5 2023

Meet the Community – David Zehnder

Community
News | Feb 28 2023

First Medication to Treat Friedreich’s Ataxia Approved on Rare Disease Day!

News | Feb 28 2023

February 2023 – Advocacy Newsletter

Advocacy
News | Jan 23 2023

A Gene-Edited Cell Therapy for an Incurable Disease: Researchers Receive USD 4.8M Grant to Treat Friedreich’s Ataxia

Industry News
News | Jan 10 2023

Dr. Stepanova Presented with $20,000 Research Grant from Uplifting Athletes

News | Jan 9 2023

Prime Medicine announces recent progress and highlights 2023 strategic priorities

New preclinical data in Friedrich’s ataxia and cystic fibrosis provided further proof-of-concept for Prime Editing’s ability to achieve ...

Industry News
News | Jan 4 2023

Hereditary Ataxias Added as Eligible Condition for CDMRP Funding!

Advocacy
News | Dec 7 2022

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

Industry News
Blog | Aug 29 2022

The Legacy of FA Woodstock & The Anonymous Estate Gift it Inspired

Events
News | Jun 1 2022

Strong Partnership Funds the 2022 Ataxian Athlete Initiative (AAI) for People with Ataxia

News | Mar 30 2022

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

Industry News